The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

NCT05789524 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to business and strategic decision

Conditions

Hemophilia a
Hemophilia B

Interventions

DRUG: SerpinPC

Sponsor

ApcinteX Ltd

Collaborators

[object Object]